EPS for Abeona Therapeutics Inc. (ABEO) Expected At $-0.23

November 10, 2018 - By Harriett Tippett

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.23 EPS on November, 21.They anticipate $0.10 EPS change or 76.92 % from last quarter’s $-0.13 EPS. After having $-0.25 EPS previously, Abeona Therapeutics Inc.’s analysts see -8.00 % EPS growth. The stock decreased 5.26% or $0.52 during the last trading session, reaching $9.36. About 591,945 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 5.07% since November 11, 2017 and is uptrending. It has underperformed by 10.55% the S&P500.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 5 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 8 analyst reports since May 14, 2018 according to SRatingsIntel. The stock has “Buy” rating by Seaport Global on Tuesday, June 5. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, May 15. On Tuesday, May 29 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Tuesday, May 22, the company rating was maintained by Jefferies. The stock has “Buy” rating by Cantor Fitzgerald on Monday, May 21. The stock has “Buy” rating by H.C. Wainwright on Tuesday, June 5. The rating was maintained by H.C. Wainwright on Monday, May 14 with “Buy”.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $448.75 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Schaeffersresearch.com which released: “2 Drug Stocks Popping on Fresh “Buy” Ratings” on October 12, 2018, also Nasdaq.com with their article: “Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights” published on November 09, 2018, Seekingalpha.com published: “Abeona Therapeutics: A Potential Leader In Gene Therapy” on November 01, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on October 12, 2018 as well as Streetinsider.com‘s news article titled: “Regenxbio (RGNX), Abeona (ABEO) Announce Worldwide Exclusive Licenses for Treatment of Four Rare Lysosomal …” with publication date: November 05, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.